YAG
SGMO

Yorkville Advisors Global’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Yorkville Advisors Global’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-22,000,000
Closed -$11.9M – 38
2025
Q2 		$11.9M Buy
+22,000,000
New +$13.1M 3.44% 3

Other funds holding SGMO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Yorkville Advisors Global's SGMO Position: Q3 2025 in Review

Yorkville Advisors Global sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q3 2025, closing a stake of 22,000,000 shares — an estimated $11.9M sold.

Yorkville Advisors Global first reported a position in SGMO in Q2 2025 and held it in 1 quarter. The position peaked at $11.9M in Q2 2025. 112 funds tracked by Wall St. Rank hold SGMO as of Q3 2025.

  • Yorkville Advisors Global reported no remaining SANGAMO THERAPEUTICS INC position as of Q3 2025 after selling out during the quarter.
  • Yorkville Advisors Global sold 22,000,000 SANGAMO THERAPEUTICS INC shares in Q3 2025, an estimated $11.9M.
  • Yorkville Advisors Global first reported a position in SANGAMO THERAPEUTICS INC in Q2 2025 and held it in 1 quarter.
  • Yorkville Advisors Global's SANGAMO THERAPEUTICS INC position peaked at $11.9M in Q2 2025.
  • 112 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q3 2025.

Based on Yorkville Advisors Global's 13F filing for Q3 2025, filed 18 Nov 2025.